logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Export All Citations
Copyright © Médecins Sans Frontières
v2.1.5758.produseast1
Showing 1 - 9 of 9 Items
Showing 1 - 9 of 9 Items
Citations
  • Download citations in various formats (CSV, BibTeX, EndNote) for use in reference managers and bibliographies.
  • Current Page (9)
  • CSV
  • BibTeX
  • EndNote
  • All Results (9)
  • CSV
  • BibTeX
  • EndNote
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country multidrug-resistant/rifampicin-resistant tuberculosis cohort

Khan U, Rich M, Franke MF, Lachenal N, Ahmed S,  et al.
2025-08-01 • Clinical Infectious Diseases
2025-08-01 • Clinical Infectious Diseases

BACKGROUND

The 2022 World Health Organization (WHO) guidelines on multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) recommend 6 months of bedaqu...

Journal Article
|
Review
Journal Article
|
Review
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Research
Journal Article
|
Letter
Journal Article
|
Research
Journal Article
|
Research

Clinical best practices for caring for people with expanded resistance to newer TB drugs

Nkomo T, Udwadia Z, Vambe D, van Rie A, Thi S,  et al.
2025-06-13 • IJTLD OPEN
2025-06-13 • IJTLD OPEN

BACKGROUND

Strains of Mycobacterium tuberculosis

Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosis

Seddon JA, Achar J, Malik AA, Hughes J, Burzynski J,  et al.
2025-06-06 • Lancet Infectious Diseases
2025-06-06 • Lancet Infectious Diseases

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A,  et al.
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country MDR/RR-TB cohort

Khan U, Rich M, Franke M, Lachenal N, Ahmed S,  et al.
2024-12-10 • Clinical Infectious Diseases
2024-12-10 • Clinical Infectious Diseases

BACKGROUND

The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A,  et al.
2024-01-29 • medRxiv
2024-01-29 • medRxiv

BACKGROUND

Aft...

Eligibility for the shorter multidrug-resistant tuberculosis regimen: ambiguities in the World Health Organization recommendations

Varaine FFV, Guglielmetti L, Huerga H, Bonnet MMB, Kiria N,  et al.
2016-10-15 • American Journal of Respiratory and Critical Care Medicine
2016-10-15 • American Journal of Respiratory and Critical Care Medicine

Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia

Hewison CCH, Bastard M, Khachatryan N, Kotrikadze T, Hayrapetyan A,  et al.
2018-07-01 • International Journal of Tuberculosis and Lung Disease
2018-07-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND AND SETTING
Bedaquiline (BDQ) was initially only available through compassionate use programmes.

OBJECTIVE
To assess the effectiveness and safety of multidrug...

Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries

Guglielmetti L, Hewison CCH, Avaliani Z, Hughes AJ, Kiria N,  et al.
2017-02-01 • International Journal of Tuberculosis and Lung Disease
2017-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of i...